---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027367"
form_type: "8-K/A"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:14:39.875172+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY

## Summary
- Revenue $12.3M, down ~3.1% YoY from $12.8M.
- Operating income $30K vs $585K; net loss $35K vs net income $516K.
- Diluted EPS $0.00 per share vs $0.02 in prior-year quarter.
- Co-CEOs cite customer overstocking from pandemic as reason for sales decline.
- Two largest customers in Contract Manufacturing segment made up 85% of revenue (91% a year ago).

## SEC filing metadata
- accession: 0001437749-22-027367
- form_type: 8-K/A
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/0001437749-22-027367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/inbp20221114_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027367
- JSON: https://secwatch.observer/filing/0001437749-22-027367.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027367.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share, EPS $0.00 per share of common stock.
  - Period: quarter ended September 30, 2022
  - Revenue: $12.3 million
  - Net income: net loss of approximately $35,000 or $0.00 per share
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%. The Company had operating income for the quarter ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/0001437749-22-027367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.